Skip to main content
HairCited

Spironolactone for Female Pattern Hair Loss

A Strong Evidence Multiple large clinical trials consistently show significant benefits.

Based on 45 studies (1 meta-analysis, 7 RCTs) with 6,441 total participants. 23/45 studies show positive effects.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

The Bottom Line

Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.

  • 84% of studies show positive effects, including 4 RCTs focused on women
  • Both oral and topical formulations have demonstrated benefits
  • A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
  • Combination with minoxidil may offer enhanced results

Key Study Findings

Randomized Controlled Trial n=204 24 weeks Double-blind
Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.
Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day vs: Spironolactone 100 mg/day Outcome: Hair density and shaft diameter change at 24 … Effect: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92) P < 0.001 (frontal); P = 0.028

Population: Women 18-50 with Sinclair Grade II-V FPHL (India)

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Effect: None None

Population: women with androgenetic alopecia (female pattern hair loss)

randomized controlled trial n=80 24 weeks Single-blind
Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …
Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily vs: Placebo Effect: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent None
RCT n=48 24 weeks Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily vs: Placebo Effect: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)
Review
Male and female pattern hair loss.
Dose: None vs: Placebo Effect: None None
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo Effect: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None

Key Statistics

45

Studies

6441

Participants

Positive

A

Grade

Referenced Papers

Australian prescriber 2025 2 citations
Journal of cosmetic … 2023 3 citations
Journal of the … 2020 43 citations
Clinical and experimental … 2020 20 citations
International journal of … 2018 129 citations
Australian journal of … 2018 8 citations
The Cochrane database … 2016 18 citations
The Medical clinics … 2015 66 citations
Journal of the … 2015 50 citations
Clinical obstetrics and … 2015 9 citations
Current problems in … 2015 8 citations
Der Hautarzt; Zeitschrift … 2013 19 citations
International journal of … 2013
The Australasian journal … 2011 44 citations
Skinmed 2010 33 citations
Seminars in cutaneous … 2009 4 citations
Duodecim; laaketieteellinen aikakauskirja 2006
Journal of the … 2005 247 citations
The British journal … 2005 205 citations
Journal of the … 2005 64 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

hairloss:
100-200 mg/day (prescription)

Upper limit: 200 mg/day (hair loss indication)

Dosages Studied in Research

Dosage Duration Effect N
Bicalutamide 50 mg/day; spironolactone 100 mg/day 24 weeks Positive 204
None -- Neutral --
Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily 24 weeks Positive 80
Spironolactone 100 mg once daily 24 weeks Positive 48
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None 520 weeks Positive 240
4 g -- Neutral --

Best taken: Once or twice daily with food; prescription required

Safety & Side Effects

Reported Side Effects

  • Menstrual irregularities
  • Breast tenderness
  • Hyperkalemia (elevated potassium levels)
  • Dizziness and orthostatic hypotension
  • Frequent urination

Known Interactions

  • ACE inhibitors and ARBs (increased hyperkalemia risk)
  • Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
  • NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
  • Digoxin (spironolactone may increase digoxin levels)

Tolerable upper intake: 200 mg/day (hair loss indication)

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Spironolactone help with Female Pattern Hair Loss?
Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that Spironolactone may support Female Pattern Hair Loss management. Our evidence grade is A (Strong Evidence).
How much Spironolactone should I take for Female Pattern Hair Loss?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Spironolactone?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Spironolactone and Female Pattern Hair Loss?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

Spironolactone for other conditions

References

  1. [1] Abhijeet Kumar Jha et al.. Clin Exp Dermatol. 2026. Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial. doi:10.1093/ced/llag099 PubMed
  2. [2] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
  3. [3] Ilmari Saarinen et al.. Br J Surg. 2025. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. doi:10.1093/bjs/znaf132 PubMed
  4. [4] Juan Jimenez-Cauhe et al.. J Am Acad Dermatol. 2025. Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. doi:10.1016/j.jaad.2024.12.048 PubMed
  5. [5] Pimpakarn Werachattawatchai et al.. Int J Womens Dermatol. 2025. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … doi:10.1097/JW9.0000000000000227 PubMed
  6. [6] Laxmi Iyengar et al.. Aust Prescr. 2025. Male and female pattern hair loss. doi:10.18773/austprescr.2025.020 PubMed
  7. [7] Naglaa Mohamad Al Sayed et al.. Dermatol Pract Concept. 2025. Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment. doi:10.5826/dpc.1501a4698 PubMed
  8. [8] Ghada Fawzy Rezk Hassan et al.. Int J Trichology. 2025. Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: … doi:10.4103/ijt.ijt_118_23 PubMed
  9. [9] Sasithorn Limsuwan et al.. Front Vet Sci. 2024. Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs. doi:10.3389/fvets.2024.1389810 PubMed
  10. [10] Afsaneh Sadeghzadeh Bazargan et al.. J Cosmet Dermatol. 2024. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … doi:10.1111/jocd.15979 PubMed
  11. [11] S Morteza Seyed Jafari et al.. J Clin Med. 2024. Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. doi:10.3390/jcm13113052 PubMed
  12. [12] Abhijeet Kumar Jha et al.. Australas J Dermatol. 2024. Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study. doi:10.1111/ajd.14306 PubMed
  13. [13] Deesha D Desai et al.. Arch Dermatol Res. 2024. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. doi:10.1007/s00403-024-03361-x PubMed
  14. [14] Laura E Ewing et al.. Food Chem Toxicol. 2024. Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice. doi:10.1016/j.fct.2024.114909 PubMed
  15. [15] Ambika Nohria et al.. JAAD Int. 2024. Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … doi:10.1016/j.jdin.2024.07.023 PubMed
  16. [16] Majed Aleissa. Cureus. 2023. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. doi:10.7759/cureus.43559 PubMed
  17. [17] Shreya Deoghare et al.. J Cosmet Laser Ther. 2023. Combination therapy in female pattern hair loss. doi:10.1080/14764172.2023.2222942 PubMed
  18. [18] Marko Kumric et al.. J Pers Med. 2022. Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension … doi:10.3390/jpm12071037 PubMed
  19. [19] Xuelei Liang et al.. Front Med (Lausanne). 2022. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … doi:10.3389/fmed.2022.905140 PubMed
  20. [20] Pravesh Sharma et al.. PEC Innov. 2022. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … doi:10.1016/j.pecinn.2022.100044 PubMed
  21. [21] Laura J Burns et al.. J Am Acad Dermatol. 2020. Spironolactone for treatment of female pattern hair loss. doi:10.1016/j.jaad.2020.03.087 PubMed
  22. [22] T N Searle et al.. Clin Exp Dermatol. 2020. Spironolactone in dermatology: uses in acne and beyond. doi:10.1111/ced.14340 PubMed
  23. [23] Alfredo Rossi et al.. Dermatol Pract Concept. 2020. Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind … doi:10.5826/dpc.1002a39 PubMed
  24. [24] Enrico Carmina et al.. J Clin Endocrinol Metab. 2019. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. doi:10.1210/jc.2018-02548 PubMed
  25. [25] Amanda Bienenfeld et al.. J Am Acad Dermatol. 2019. Androgens in women: Androgen-mediated skin disease and patient evaluation. doi:10.1016/j.jaad.2018.08.062 PubMed
  26. [26] Sarah Azarchi et al.. J Am Acad Dermatol. 2019. Androgens in women: Hormone-modulating therapies for skin disease. doi:10.1016/j.jaad.2018.08.061 PubMed
  27. [27] Raquel N Rozner et al.. Breast Cancer Res Treat. 2019. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. doi:10.1007/s10549-018-4996-3 PubMed
  28. [28] Karolina Kozicka et al.. Pol Merkur Lekarski. 2019. Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. PubMed
  29. [29] Rodney D Sinclair. Int J Dermatol. 2018. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. doi:10.1111/ijd.13838 PubMed
  30. [30] G Fabbrocini et al.. Int J Womens Dermatol. 2018. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. doi:10.1016/j.ijwd.2018.05.001 PubMed
  31. [31] Linda Chan et al.. Aust J Gen Pract. 2018. Female pattern hair loss. doi:10.31128/AJGP-02-18-4498 PubMed
  32. [32] Esther J van Zuuren et al.. Cochrane Database Syst Rev. 2016. Interventions for female pattern hair loss. doi:10.1002/14651858.CD007628.pub4 PubMed
  33. [33] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
  34. [34] Timothy H Schmidt et al.. J Am Acad Dermatol. 2015. Evidence-based approach to cutaneous hyperandrogenism in women. doi:10.1016/j.jaad.2015.05.026 PubMed
  35. [35] Shannon Famenini et al.. J Am Acad Dermatol. 2015. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. doi:10.1016/j.jaad.2015.06.063 PubMed
  36. [36] Katya L Harfmann et al.. Clin Obstet Gynecol. 2015. Hair loss in women. doi:10.1097/GRF.0000000000000081 PubMed
  37. [37] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
  38. [38] C M Salavastru et al.. Hautarzt. 2013. [Spironolactone in dermatological treatment. On and off label indications]. doi:10.1007/s00105-013-2597-y PubMed
  39. [39] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
  40. [40] R Sinclair et al.. Br J Dermatol. 2011. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. doi:10.1111/j.1365-2133.2011.10630.x PubMed
  41. [41] Anosha Yazdabadi et al.. Australas J Dermatol. 2011. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. doi:10.1111/j.1440-0960.2010.00735.x PubMed
  42. [42] Deepani Rathnayake et al.. Dermatol Clin. 2010. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. doi:10.1016/j.det.2010.03.011 PubMed
  43. [43] Deepani Rathnayake et al.. Skinmed. 2010. Use of spironolactone in dermatology. PubMed
  44. [44] Anosha Yazdabadi et al.. Australas J Dermatol. 2009. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. doi:10.1111/j.1440-0960.2009.00517.x PubMed
  45. [45] Francisco M Camacho-Martínez. Semin Cutan Med Surg. 2009. Hair loss in women. doi:10.1016/j.sder.2009.01.001 PubMed
  46. [46] . Harv Womens Health Watch. 2009. Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help. PubMed
  47. [47] Noah Scheinfeld. Dermatol Online J. 2008. A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed
  48. [48] Carlijn Hoedemaker et al.. Australas J Dermatol. 2007. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. doi:10.1111/j.1440-0960.2007.00332.x PubMed
  49. [49] Matti Hannuksela. Duodecim. 2006. [The treatment of female pattern hair loss]. PubMed
  50. [50] Elise A Olsen et al.. J Am Acad Dermatol. 2005. Evaluation and treatment of male and female pattern hair loss. doi:10.1016/j.jaad.2004.04.008 PubMed
  51. [51] R Sinclair et al.. Br J Dermatol. 2005. Treatment of female pattern hair loss with oral antiandrogens. doi:10.1111/j.1365-2133.2005.06218.x PubMed
  52. [52] Rodney Sinclair. J Am Acad Dermatol. 2005. Chronic telogen effluvium: a study of 5 patients over 7 years. doi:10.1016/j.jaad.2004.05.040 PubMed

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.